Fennec's Pedmark meets in Phase III to prevent hearing loss associated with platinum-based chemotherapies

In October, Fennec Pharmaceuticals Inc. (TSX:FRX; NASDAQ:FENC) reported top-line data from the Phase III SIOPEL 6 trial in 99 children receiving platinum-based

Read the full 229 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE